James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Selling the Craftsman Brand Won’t Fix Sears Holdings Corp (SHLD)

Sears Holdings Corp (NASDAQ:SHLD) is tearing off another piece of its sinking ship in an effort to build a fire on the deck.

Why Dollar Tree, Inc. (DLTR), Dr Pepper Snapple Group Inc. (DPS) and Silver Wheaton Corp. (USA) (SLW) Are 3 of Today’s Worst Stocks

Dr Pepper Snapple (DPS), Dollar Tree (DLTR) and Silver Wheaton (SLW) never even had a chance of making gains on Tuesday.

Why Walt Disney Co (DIS) Is Far Better Off With Netflix, Inc. (NFLX)

Disney stock (DIS) could use the juice from an acquisition. And rumors of interest in Netflix (NFLX) seem far more appealing than Twitter (TWTR).

Why Deutsche Bank AG (USA) (DB), Goldcorp Inc. (USA) (GG) and KBR, Inc. (KBR) Are 3 of Today’s Worst Stocks

Goldcorp (GG), KBR and Deutsche Bank (DB) never even had a prayer of bullishness on Monday. Here's what you need to know.

10 Biotech Stocks to Put on Your Radar This Quarter

Q4 is usually a winner for biotech stocks, but these stocks could deliver more than their fair share of wins during the coming three months.